

AMENDMENTS TO THE CLAIMS

1. (Currently Amended): ~~A system for the production of recombinant N-glycosylated target proteins, the system comprising a~~ prokaryotic organism into which is introduced ~~[[a]]~~ genetic information comprising nucleic acids encoding for:

a) glycosyltransferases of a type that assembles an oligosaccharide on a lipid carrier;

b) one or more recombinant target proteins comprising a consensus sequence Asn-X-Ser(Thr), wherein X can be any amino acid except Pro; and

c) an oligosaccharyl transferase;

wherein said oligosaccharyl transferase links said oligosaccharide to said consensus sequence of said one or more recombinant target proteins.

~~a metabolic apparatus capable of carrying out the requested N-glycosylation of the target protein, wherein said prokaryotic organism also contains the genetic information required for the expression of one or more recombinant target proteins.~~

2. (Canceled).

3. (Currently Amended): The ~~system~~ prokaryotic organism of claim 1, wherein the prokaryotic organism is *Escherichia coli*.

4. (Currently Amended): The ~~system~~ prokaryotic organism of claim 1 ~~[[2]]~~, wherein the prokaryotic organism ~~[[is]]~~ produces~~[[ing]]~~ N-glycanes with a specific structure which is defined by the type of the specific glycosyltransferases.

5. (Withdrawn): A method of producing recombinant *N*-glycosylated target proteins, the method comprising the introduction of a genetic information encoding for a metabolic apparatus capable of carrying out the requested *N*-glycosylation of the target protein into a prokaryotic organism, wherein also the genetic information required for the expression of one or more recombinant target proteins is introduced into said prokaryotic organism.
6. (Withdrawn): The method of claim 5, wherein the metabolic apparatus comprises specific glycosyltransferases for the assembly of the oligosaccharide on a lipid carrier and an OTase, the OTase covalently linking this oligosaccharide to specific residues of the desired target protein.
7. (Withdrawn): The method of one of claims 5 or 6, wherein the prokaryotic organism is *Escherichia coli*.
8. (Withdrawn): The method of claim 6, wherein - by selection of specific glycosyltransferases - the prokaryotic organism is producing *N*-glycanes with a specific structure which is defined by the type of the specific glycosyltransferases.
9. (Withdrawn): Utilization of the system of claim 1 for the production of target proteins for the development of medicaments or for the production of medicaments for the treatment of humans or animals or plant.
10. (Withdrawn - currently amended): Proteins for nutrition and/or pharmaceutical purposes, produced with the system of ~~one of~~ claim[[s]] 1.
11. (Withdrawn): Vaccines, Cytokines and the like medicaments for human or animals or plant, produced with the system of claim 1.
12. (Withdrawn - currently amended): Industrial enzymes, functional food, cosmetics, packaging materials or textiles comprising proteins produced with the system of claim 1.

13. (Withdrawn): Utilization of a medicament produced with the system of claim 1 for the therapy of human or animal or plant diseases.
14. (Canceled).
15. (Currently Amended): The system prokaryotic organism of claim 3, wherein the *Escherichia coli* ~~prokaryotic organism~~ ^{[[is]]} produces^{[[ing]]} N-glycanes with a specific structure which is defined by the type of the specific glycosyltransferases.
16. (Withdrawn): Utilization of the method of claim 5 for the production of target proteins for the development of medicaments or for the production of medicaments for the treatment of humans or animals or plant.
17. (Withdrawn): Proteins for nutrition and/or pharmaceutical purposes, produced with the method of claim 5.
18. (Withdrawn): Vaccines, Cytokines and the like medicaments for human or animals or plant, produced with the method of claim 5.
19. (Withdrawn): Industrial enzymes, functional food, cosmetics, packaging materials or textiles comprising proteins produced with the method of claim 5.
20. (Withdrawn): Utilization of a medicament produced with the method of claim 5 for the therapy of human or animal or plant diseases.